Long-term treatment of patient with metastatic melanoma of the trunk

被引：0
|
作者：
Kempa-Kaminska, Natasza [1 ]
机构：
[1] Dolnoslaskie Ctr Onkol Wroclawiu, Oddzial Onkol Klin, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷
关键词：
immunotherapy; melanoma; vemurafenib; hepatotoxicity;
D O I：
10.5603/OCP.2018.0063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Currently there has been a huge development in melanoma therapy. There are drugs with high efficacy, but also with a completely new toxicity profile. Below is a case report of a patient treated for metastatic melanoma of the body. Treatment included vemurafenib and immunotherapy in the form of pembrolizumab, a monoclonal antibody blocking PD-1 receptor. Among toxicity, dermatological effects of vemurafenib treatment and hepatotoxicity during immunotherapy were observed mainly in case of treatment with vemurafenib. The applied treatment allowed for several years of survival of the patient in good general condition.
引用
收藏
页码：A19 / A22
页数：4
相关论文
共 50 条
  • [1] Evolving impact of long-term survival results on metastatic melanoma treatment
    Michielin, Olivier
    Atkins, Michael B.
    Koon, Henry B.
    Dummer, Reinhard
    Ascierto, Paolo Antonio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [2] Long-term survival of a metastatic cerebral melanoma
    Banayan, A
    Vital, C
    NEUROCHIRURGIE, 1998, 44 (04) : 275 - 277
  • [3] Long-Term Survivors with Metastatic Uveal Melanoma
    Buzzacco, Dominic M.
    Abdel-Rahman, Mohamed H.
    Park, Stanley
    Davidorf, Frederick
    Olencki, Thomas
    Cebulla, Colleen M.
    OPEN OPHTHALMOLOGY JOURNAL, 2012, 6 : 49 - 53
  • [4] Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
    Charlée Nardin
    Sophie Borot
    Marie-Astride Beaudoin
    Françoise Cattin
    Eve Puzenat
    Anne-Sophie Gauthier
    Franck Schillo
    Christophe Borg
    François Aubin
    Investigational New Drugs, 2019, 37 : 375 - 377
  • [5] Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo
    Takeshi Fukumoto
    Susumu Fujiwara
    Masanobu Sakaguchi
    Masahiro Oka
    Naomi Kiyota
    Yasuo Ejima
    Koichi Nakajima
    Chikako Nishigori
    European Journal of Dermatology, 2017, 27 : 177 - 178
  • [6] Fever as a factor contributing to long-term survival in a patient with metastatic melanoma: A case report
    Wrotek, Sylwia
    Brycht, Lukasz
    Wrotek, Weronika
    Kozak, Wieslaw
    COMPLEMENTARY THERAPIES IN MEDICINE, 2018, 38 : 7 - 10
  • [7] Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
    Nardin, Charlee
    Borot, Sophie
    Beaudoin, Marie-Astride
    Cattin, Francoise
    Puzenat, Eve
    Gauthier, Anne-Sophie
    Schillo, Franck
    Borg, Christophe
    Aubin, Francois
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 375 - 377
  • [8] Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo
    Fukumoto, Takeshi
    Fujiwara, Susumu
    Sakaguchi, Masanobu
    Oka, Masahiro
    Kiyota, Naomi
    Ejima, Yasuo
    Nakajima, Koichi
    Nishigori, Chikako
    EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (02) : 177 - 178
  • [9] LONG-TERM RESULTS OF MELANOMA TREATMENT
    NIVINSKAYA, MM
    ACTA UNIO INTERNATIONALIS CONTRA CANCRUM, 1964, 20 (08) : 1804 - +
  • [10] Long-term survivors after immunotherapy for metastatic melanoma
    Tseng, William W.
    Leong, Stanley P. L.
    IMMUNOLOGY LETTERS, 2011, 139 (1-2) : 117 - 118
12345